| treatment |
|
comparator |
All cause death | Coronary death | Coronary event | Cardiovascular death | Fatal MI | myocardial infarction (fatal and non fatal) | Death from any cause or hospitalization for any reason | hospitalisation for heart failure | Sudden death | cardiac death | reinfarction | cardiovascular events | cardiac event (fatal and non fatal ) | NYHA class improvement |
|
|
| Metoprolol | acute myocardial infarction, in immediate beta-blockers | vs placebo | NS | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 0.89 [0.71 1.12] | p=1.00 | 0 | 7302 | 4 | MIAMI Trial Research Group , Von Essen , Waagstein , TIMI IIB, | | Coronary death | no data | | Coronary event | no data | | Cardiovascular death | no data | | Fatal MI | no data | | myocardial infarction (fatal and non fatal) | no data | | Death from any cause or hospitalization for any reason | no data | | hospitalisation for heart failure | no data | | Sudden death | no data | | cardiac death | no data | | reinfarction | no data | | cardiovascular events | no data | | cardiac event (fatal and non fatal ) | no data | | NYHA class improvement | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| MIAMI Trial Research Group , 1985 | Metoprolol (initial dose intravenously) | | | | Von Essen , 1982 | Metoprolol (initial dose intravenously) | | | | Waagstein , 1975 | Practolol, (initial dose intravenously) H87/07, or metoprolol | | | | TIMI IIB, 1989 | Metoprolol (initial dose intravenously) (15 mg) | | |
|
| Metoprolol | acute myocardial infarction, in long term beta-blockers | vs placebo | by 21% | - | - | NS | - | - | - | - | NS | NS | by 38% | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 0.79 [0.65 0.96] | p=0.04 | 0 | 5408 | 5 | Hjalmarson , LIT Research Group , Manger Cats , Rehnqvist , Salathia , | | Coronary death | no data | | Coronary event | no data | | Cardiovascular death | 0.93 [0.68 1.28] | p=1.00 | 0 | 2395 | 1 | LIT Research Group , | | Fatal MI | no data | | myocardial infarction (fatal and non fatal) | no data | | Death from any cause or hospitalization for any reason | no data | | hospitalisation for heart failure | no data | | Sudden death | 0.68 [0.42 1.09] | p=1.00 | 0 | 3195 | 2 | LIT Research Group , Salathia , | | cardiac death | 0.93 [0.72 1.21] | p=1.00 | 0 | 3195 | 2 | LIT Research Group , Salathia , | | reinfarction | 0.62 [0.43 0.88] | p=0.04 | 0 | 1696 | 2 | Hjalmarson , Rehnqvist , | | cardiovascular events | no data | | cardiac event (fatal and non fatal ) | no data | | NYHA class improvement | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Hjalmarson , 1981 | Metoprolol 100mg twice daily (initial dose intravenously) | placebo | patients aged between 40 -74 years with suspected MI and onset of infarction within the previous 48h | | LIT Research Group , 1987 | Metoprolol 100 mg bid | placebo | patients, 45 to 74 yearsof age, surviving a recent acute MI | | Manger Cats , 1983 | Metoprolol 100mg twice daily | placebo | MI, NYHA Class I or II and <=70 y | | Rehnqvist , 1983 | Metoprolol 100mg twice daily | placebo | AMI patients <70 years in sinus rythm without complete BBB | | Salathia , 1985 | Metoprolol 100 mg twice daily for one year (initial dose intravenously) | placebo | patients with acute myocardial infarction |
|
| Metoprolol | heart failure, in all type of heart failure | vs placebo | by 31% | - | - | by 37% | - | - | NS | NS | by 40% | - | - | - | - | NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 0.69 [0.56 0.84] | p=0.04 | 0 | 4899 | 6 | MDC (Waagstein), MERIT-HF, Engelmeier, Fisher, Eichhorn, RESOLVD, | | Coronary death | no data | | Coronary event | no data | | Cardiovascular death | 0.63 [0.50 0.80] | p=0.04 | 0 | 3991 | 1 | MERIT-HF, | | Fatal MI | no data | | myocardial infarction (fatal and non fatal) | no data | | Death from any cause or hospitalization for any reason | 0.77 [0.49 1.20] | p=1.00 | 0 | 383 | 1 | MDC (Waagstein), | | hospitalisation for heart failure | 0.64 [0.41 1.02] | p=1.00 | 0 | 482 | 4 | MDC (Waagstein), Engelmeier, Fisher, Eichhorn, | | Sudden death | 0.60 [0.45 0.80] | p=0.04 | 0 | 3991 | 1 | MERIT-HF, | | cardiac death | no data | | reinfarction | no data | | cardiovascular events | no data | | cardiac event (fatal and non fatal ) | no data | | NYHA class improvement | 1.41 [0.94 2.11] | p=1.00 | 0 | 482 | 4 | MDC (Waagstein), Engelmeier, Fisher, Eichhorn, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| MDC (Waagstein), 1993 | metoprolol target dose 100-150 mg daily (dose divided into two or three per day) | placebo | patient with heart failure due to idiopathic dilated cardiomyopathy (NYHA 1-3) and EF<40% | | MERIT-HF, 1999 | metoprolol CR/XL at target dose of 200 mg once daily | placebo | patients with chronic heart
failure in New York Heart Association (NYHA) functional class II–IV and with ejection fraction of 0·40 or less, stabilised with optimum standard therapy | | Engelmeier, 1985 | metoprolol | placebo | NYHA 2-4, IDC | | Fisher, 1994 | metoprolol | placebo | NYHA 3-4, CAD | | Eichhorn, 1994 | metoprolol | placebo | NYHA 2-3, IDC | | RESOLVD, 2000 | metoprolol CR 200 mg/d | placebo | CHF of mixed causes, patients with symptomatic CHF(NYHA II to IV), a 6-minute walk distance of <500 m, and an LV ejection fraction (EF) of<40% |
|
| Metoprolol | heart failure, in elderly patients | vs placebo | NS | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 0.91 [0.75 1.11] | p=1.00 | 0 | -18 | 1 | BEST (elderly subgroup), | | Coronary death | no data | | Coronary event | no data | | Cardiovascular death | no data | | Fatal MI | no data | | myocardial infarction (fatal and non fatal) | no data | | Death from any cause or hospitalization for any reason | no data | | hospitalisation for heart failure | no data | | Sudden death | no data | | cardiac death | no data | | reinfarction | no data | | cardiovascular events | no data | | cardiac event (fatal and non fatal ) | no data | | NYHA class improvement | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| BEST (elderly subgroup), 2001 | Metoprolol | placebo | Upper tertile age |
|
| Acebutolol | acute myocardial infarction, in immediate beta-blockers | vs placebo | NS | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 0.86 [0.02 46.71] | p=1.00 | 0 | 26 | 1 | Azancot, | | Coronary death | no data | | Coronary event | no data | | Cardiovascular death | no data | | Fatal MI | no data | | myocardial infarction (fatal and non fatal) | no data | | Death from any cause or hospitalization for any reason | no data | | hospitalisation for heart failure | no data | | Sudden death | no data | | cardiac death | no data | | reinfarction | no data | | cardiovascular events | no data | | cardiac event (fatal and non fatal ) | no data | | NYHA class improvement | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Azancot, 1982 | Acebutolol (initial dose intravenously) | control | patients seen within 24 hours after the onset of uncomplicated anterior transmural myocardial infarction |
|
| Acebutolol | acute myocardial infarction, in long term beta-blockers | vs placebo | by 48% | - | - | by 59% | NS | NS | - | - | NS | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 0.52 [0.28 0.95] | p=0.04 | 0 | 607 | 1 | APSI, | | Coronary death | no data | | Coronary event | no data | | Cardiovascular death | 0.41 [0.21 0.83] | p=0.04 | 0 | 607 | 1 | APSI, | | Fatal MI | 0.44 [0.11 1.73] | p=1.00 | 0 | 607 | 1 | APSI, | | myocardial infarction (fatal and non fatal) | 0.85 [0.35 2.08] | p=1.00 | 0 | 607 | 1 | APSI, | | Death from any cause or hospitalization for any reason | no data | | hospitalisation for heart failure | no data | | Sudden death | 0.69 [0.24 1.97] | p=1.00 | 0 | 607 | 1 | APSI, | | cardiac death | no data | | reinfarction | no data | | cardiovascular events | no data | | cardiac event (fatal and non fatal ) | no data | | NYHA class improvement | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| APSI, 1990 | Acebutolol 200mg twice daily | placebo | patient surviving MI at hight risk |
|
| Atenolol | acute myocardial infarction, in immediate beta-blockers | vs placebo | NS | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 0.94 [0.86 1.03] | p=1.00 | 0 | 16698 | 3 | ISIS1 Collaborative Group , Van de Werf , Yusuf , | | Coronary death | no data | | Coronary event | no data | | Cardiovascular death | no data | | Fatal MI | no data | | myocardial infarction (fatal and non fatal) | no data | | Death from any cause or hospitalization for any reason | no data | | hospitalisation for heart failure | no data | | Sudden death | no data | | cardiac death | no data | | reinfarction | no data | | cardiovascular events | no data | | cardiac event (fatal and non fatal ) | no data | | NYHA class improvement | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| ISIS1 Collaborative Group , 1986 | Atenolol (initial dose intravenously) | control | patients within 5 h the onset of suspected acute myocardial infarction | | Van de Werf , 1993 | Atenolol | | | | Yusuf , 1980 | Atenolol (initial dose intravenously) | | |
|
| Betaxolol | acute myocardial infarction, in immediate beta-blockers | vs placebo | NS | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 0.94 [0.02 50.42] | p=1.00 | 0 | 31 | 1 | Yang , | | Coronary death | no data | | Coronary event | no data | | Cardiovascular death | no data | | Fatal MI | no data | | myocardial infarction (fatal and non fatal) | no data | | Death from any cause or hospitalization for any reason | no data | | hospitalisation for heart failure | no data | | Sudden death | no data | | cardiac death | no data | | reinfarction | no data | | cardiovascular events | no data | | cardiac event (fatal and non fatal ) | no data | | NYHA class improvement | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Yang , 1987 | Betaxolol | | |
|
| Bisoprolol | heart failure, in all type of heart failure | vs placebo | by 29% | - | - | NS | - | - | by 18% | by 34% | by 42% | - | - | - | - | NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 0.71 [0.58 0.86] | p=0.04 | 0 | 3288 | 2 | CIBIS, CIBIS II, | | Coronary death | no data | | Coronary event | no data | | Cardiovascular death | 0.68 [0.44 1.05] | p=1.00 | 0 | 641 | 1 | CIBIS, | | Fatal MI | no data | | myocardial infarction (fatal and non fatal) | no data | | Death from any cause or hospitalization for any reason | 0.82 [0.71 0.95] | p=0.04 | 0 | 3288 | 2 | CIBIS, CIBIS II, | | hospitalisation for heart failure | 0.66 [0.45 0.97] | p=0.04 | 0 | 641 | 1 | CIBIS, | | Sudden death | 0.58 [0.40 0.83] | p=0.04 | 0 | 2647 | 1 | CIBIS II, | | cardiac death | no data | | reinfarction | no data | | cardiovascular events | no data | | cardiac event (fatal and non fatal ) | no data | | NYHA class improvement | 1.42 [0.95 2.14] | p=1.00 | 0 | 641 | 1 | CIBIS, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| CIBIS, 1994 | bisoprolol 5mg/d | placebo | stable chronic idiopathic dilated cardiomyopathy heart failure NYHA 3-4, EF<40% | | CIBIS II, 1999 | Bisoprolol target dose 10mg/daily | control | chronic herat failure, ejection fraction<=35%, NYHA 3-4 |
|
| Bisoprolol | heart failure, in elderly patients | vs placebo | by 30% | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 0.70 [0.50 0.98] | p=0.04 | 0 | -18 | 1 | CIBIS II (elderly subgroup), | | Coronary death | no data | | Coronary event | no data | | Cardiovascular death | no data | | Fatal MI | no data | | myocardial infarction (fatal and non fatal) | no data | | Death from any cause or hospitalization for any reason | no data | | hospitalisation for heart failure | no data | | Sudden death | no data | | cardiac death | no data | | reinfarction | no data | | cardiovascular events | no data | | cardiac event (fatal and non fatal ) | no data | | NYHA class improvement | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| CIBIS II (elderly subgroup), 1999 | Bisoprolol | placebo | Patients aged 71 years and older |
|
| Bucindolol | heart failure, in all type of heart failure | vs placebo | NS | - | - | NS | - | - | - | by 17% | - | - | - | - | - | NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 0.91 [0.78 1.07] | p=1.00 | 0 | 2924 | 4 | BEST, Pollock, Woodley, Bristow, | | Coronary death | no data | | Coronary event | no data | | Cardiovascular death | 0.88 [0.74 1.04] | p=1.00 | 0 | 2708 | 1 | BEST, | | Fatal MI | no data | | myocardial infarction (fatal and non fatal) | no data | | Death from any cause or hospitalization for any reason | no data | | hospitalisation for heart failure | 0.83 [0.71 0.97] | p=0.04 | 0 | 2924 | 4 | BEST, Pollock, Woodley, Bristow, | | Sudden death | no data | | cardiac death | no data | | reinfarction | no data | | cardiovascular events | no data | | cardiac event (fatal and non fatal ) | no data | | NYHA class improvement | 1.35 [0.69 2.62] | p=1.00 | 0 | 197 | 2 | Woodley, Bristow, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| BEST, 2001 | bucindolol titrated to 50mg txice daily | placebo | patients with heart failure NYHA class III or IV and a left ventricular ejection fraction of 35 percent or lower | | Pollock, 1990 | bucindolol target dose 100mg twice daily | placebo | Patienst with stable, chronic heart failure with a dilated cardiomyopathy due to ischemic or isopathic causes | | Woodley, 1991 | bucindolol | placebo | NYHA 2-3, IDC/CAD | | Bristow, 1994 | bucindolol | placebo | NYHA 2-3, IDC |
|
| Bucindolol | heart failure, in elderly patients | vs placebo | by 30% | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 0.70 [0.53 0.92] | p=0.04 | 0 | -18 | 1 | MERIT-HF (elderly subgroup), | | Coronary death | no data | | Coronary event | no data | | Cardiovascular death | no data | | Fatal MI | no data | | myocardial infarction (fatal and non fatal) | no data | | Death from any cause or hospitalization for any reason | no data | | hospitalisation for heart failure | no data | | Sudden death | no data | | cardiac death | no data | | reinfarction | no data | | cardiovascular events | no data | | cardiac event (fatal and non fatal ) | no data | | NYHA class improvement | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| MERIT-HF (elderly subgroup), 1999 | Bucindolol | placebo | Patients aged 65 years and olderwith chronic heart failure in NYHA functional class II-IV and with ejection fraction of 0.40 or less, stabilised with optimum standard therapy |
|
| Labetalol | acute myocardial infarction, in immediate beta-blockers | vs placebo | NS | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 1.71 [0.64 4.60] | p=1.00 | 0 | 166 | 1 | Heber , | | Coronary death | no data | | Coronary event | no data | | Cardiovascular death | no data | | Fatal MI | no data | | myocardial infarction (fatal and non fatal) | no data | | Death from any cause or hospitalization for any reason | no data | | hospitalisation for heart failure | no data | | Sudden death | no data | | cardiac death | no data | | reinfarction | no data | | cardiovascular events | no data | | cardiac event (fatal and non fatal ) | no data | | NYHA class improvement | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Heber , 1987 | Labetalol (initial dose intravenously) | control | patients with suspected myocardial infarction |
|
| Nebivolol | heart failure, in all type of heart failure | vs placebo | NS | - | - | NS | - | - | NS | NS | by 37% | - | - | - | - | NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 0.88 [0.70 1.10] | p=1.00 | 0 | 2164 | 3 | Lechat, Wisenbaugh, SENIORS, | | Coronary death | no data | | Coronary event | no data | | Cardiovascular death | 0.84 [0.65 1.09] | p=1.00 | 0 | 2128 | 1 | SENIORS, | | Fatal MI | no data | | myocardial infarction (fatal and non fatal) | no data | | Death from any cause or hospitalization for any reason | 0.88 [0.73 1.05] | p=1.00 | 0 | 2128 | 1 | SENIORS, | | hospitalisation for heart failure | 1.09 [0.06 19.07] | p=1.00 | 0 | 36 | 2 | Lechat, Wisenbaugh, | | Sudden death | 0.63 [0.42 0.92] | p=0.04 | 0 | 2128 | 1 | SENIORS, | | cardiac death | no data | | reinfarction | no data | | cardiovascular events | no data | | cardiac event (fatal and non fatal ) | no data | | NYHA class improvement | 1.00 [0.02 60.00] | p=1.00 | 0 | 12 | 1 | Lechat, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Lechat, 1991 | nebivolol 5mg/d | placebo | NYHA 3-4 | | Wisenbaugh, 1993 | nebivolol | placebo | patients with dilated idiopathic or ischemic cardiomyopathy (ejection fraction 0.15 to 0.40) in stable NYHA class II or III | | SENIORS, 2005 | nebivolol (titrated from 1.25 mg once
daily to 10 mg once daily) | placebo | patients aged 70 years with a
history of heart failure (hospital admission for heart failure within the previous year
or known ejection fraction 35%), |
|
| Nebivolol | heart failure, in elderly patients | vs placebo | NS | - | - | NS | - | - | NS | - | by 37% | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 0.88 [0.70 1.10] | p=1.00 | 0 | 2128 | 1 | SENIORS, | | Coronary death | no data | | Coronary event | no data | | Cardiovascular death | 0.84 [0.65 1.09] | p=1.00 | 0 | 2128 | 1 | SENIORS, | | Fatal MI | no data | | myocardial infarction (fatal and non fatal) | no data | | Death from any cause or hospitalization for any reason | 0.88 [0.73 1.05] | p=1.00 | 0 | 2128 | 1 | SENIORS, | | hospitalisation for heart failure | no data | | Sudden death | 0.63 [0.42 0.92] | p=0.04 | 0 | 2128 | 1 | SENIORS, | | cardiac death | no data | | reinfarction | no data | | cardiovascular events | no data | | cardiac event (fatal and non fatal ) | no data | | NYHA class improvement | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| SENIORS, 2005 | nebivolol (titrated from 1.25 mg once
daily to 10 mg once daily) | placebo | patients aged 70 years with a
history of heart failure (hospital admission for heart failure within the previous year
or known ejection fraction 35%), |
|
| Oxprenolol | acute myocardial infarction, in immediate beta-blockers | vs placebo | NS | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 1.27 [0.80 2.02] | p=1.00 | 0 | 1108 | 4 | CPRG , Fuccella , Lombardo , Wilcox , | | Coronary death | no data | | Coronary event | no data | | Cardiovascular death | no data | | Fatal MI | no data | | myocardial infarction (fatal and non fatal) | no data | | Death from any cause or hospitalization for any reason | no data | | hospitalisation for heart failure | no data | | Sudden death | no data | | cardiac death | no data | | reinfarction | no data | | cardiovascular events | no data | | cardiac event (fatal and non fatal ) | no data | | NYHA class improvement | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| CPRG , 1981 | Oxprenolol | | | | Fuccella , 1968 | Oxprenolol | | | | Lombardo , 1979 | Oxprenolol | | | | Wilcox , 1980 | Oxprenolol | | |
|
| Oxprenolol | acute myocardial infarction, in long term beta-blockers | vs placebo | NS | - | - | NS | NS | by 24% | - | - | NS | NS | NS | - | NS | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 0.94 [0.73 1.21] | p=1.00 | 0 | 3817 | 3 | EIS , Schwartz (high risk and low risk) , Taylor , | | Coronary death | no data | | Coronary event | no data | | Cardiovascular death | 0.91 [0.64 1.29] | p=1.00 | 0 | 2714 | 2 | EIS , Schwartz (high risk and low risk) , | | Fatal MI | 2.02 [0.93 4.39] | p=1.00 | 0 | 2714 | 2 | EIS , Schwartz (high risk and low risk) , | | myocardial infarction (fatal and non fatal) | 0.76 [0.58 0.99] | p=0.04 | 0 | 2076 | 2 | Schwartz (high risk and low risk) , Taylor , | | Death from any cause or hospitalization for any reason | no data | | hospitalisation for heart failure | no data | | Sudden death | 1.07 [0.61 1.89] | p=1.00 | 0 | 1741 | 1 | EIS , | | cardiac death | 1.67 [0.89 3.14] | p=1.00 | 0 | 1741 | 1 | EIS , | | reinfarction | 0.84 [0.58 1.22] | p=1.00 | 0 | 2076 | 2 | Schwartz (high risk and low risk) , Taylor , | | cardiovascular events | no data | | cardiac event (fatal and non fatal ) | 0.87 [0.65 1.17] | p=1.00 | 0 | 1103 | 1 | Taylor , | | NYHA class improvement | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| EIS , 1984 | Oxprenolol slow release 160 mg b.i.d. | placebo | patients 35 to 69 years whohas survived acute myocardial infarction | | Schwartz (high risk and low risk) , 1992 | Oxprenolol 160mg daily | placebo | patients surviving MI with or without complication by either ventricular tachycardia or fibrillation | | Taylor , 1982 | Oxprenolol 40mg twice daily | placebo | Men 35 to 65 years old who had an acute myocardial infarction between 1 and 90 months reviously |
|
| Pindolol | acute myocardial infarction, in immediate beta-blockers | vs placebo | NS | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 1.00 [0.06 16.44] | p=1.00 | 0 | 100 | 1 | Owensby , | | Coronary death | no data | | Coronary event | no data | | Cardiovascular death | no data | | Fatal MI | no data | | myocardial infarction (fatal and non fatal) | no data | | Death from any cause or hospitalization for any reason | no data | | hospitalisation for heart failure | no data | | Sudden death | no data | | cardiac death | no data | | reinfarction | no data | | cardiovascular events | no data | | cardiac event (fatal and non fatal ) | no data | | NYHA class improvement | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Owensby , 1984 | Pindolol (initial dose intravenously) | | |
|
| Pindolol | acute myocardial infarction, in long term beta-blockers | vs placebo | NS | - | - | - | NS | - | - | - | NS | NS | NS | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 0.97 [0.62 1.52] | p=1.00 | 0 | 529 | 1 | Australian and Swedish study, | | Coronary death | no data | | Coronary event | no data | | Cardiovascular death | no data | | Fatal MI | 0.94 [0.59 1.50] | p=1.00 | 0 | 529 | 1 | Australian and Swedish study, | | myocardial infarction (fatal and non fatal) | no data | | Death from any cause or hospitalization for any reason | no data | | hospitalisation for heart failure | no data | | Sudden death | 0.91 [0.53 1.57] | p=1.00 | 0 | 529 | 1 | Australian and Swedish study, | | cardiac death | 0.94 [0.59 1.50] | p=1.00 | 0 | 529 | 1 | Australian and Swedish study, | | reinfarction | 0.93 [0.42 2.09] | p=1.00 | 0 | 529 | 1 | Australian and Swedish study, | | cardiovascular events | no data | | cardiac event (fatal and non fatal ) | no data | | NYHA class improvement | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Australian and Swedish study, 1983 | Pindolol 15 mg daily | placebo | patients who had electrical and/or mechanical complications after an acute myocardial infarction |
|
| Practolol | acute myocardial infarction, in immediate beta-blockers | vs placebo | NS | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 1.17 [0.71 1.95] | p=1.00 | 0 | 486 | 5 | Evemy , Johansson , Macleod , Snow , Thompson , | | Coronary death | no data | | Coronary event | no data | | Cardiovascular death | no data | | Fatal MI | no data | | myocardial infarction (fatal and non fatal) | no data | | Death from any cause or hospitalization for any reason | no data | | hospitalisation for heart failure | no data | | Sudden death | no data | | cardiac death | no data | | reinfarction | no data | | cardiovascular events | no data | | cardiac event (fatal and non fatal ) | no data | | NYHA class improvement | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Evemy , 1978 | Practolol (initial dose intravenously) | | | | Johansson , 1980 | Practolol (initial dose intravenously) then atenolol | | | | Macleod , 1980 | Practolol (initial dose intravenously) | | | | Snow , 1980 | Practolol | | | | Thompson , 1979 | Practolol | | |
|
| Practolol | acute myocardial infarction, in long term beta-blockers | vs placebo | NS | - | - | - | - | - | - | - | by 43% | NS | NS | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 0.80 [0.61 1.04] | p=1.00 | 0 | 3053 | 1 | Multicentre international , | | Coronary death | no data | | Coronary event | no data | | Cardiovascular death | no data | | Fatal MI | no data | | myocardial infarction (fatal and non fatal) | no data | | Death from any cause or hospitalization for any reason | no data | | hospitalisation for heart failure | no data | | Sudden death | 0.57 [0.35 0.92] | p=0.04 | 0 | 3053 | 1 | Multicentre international , | | cardiac death | 0.75 [0.56 1.00] | p=1.00 | 0 | 3053 | 1 | Multicentre international , | | reinfarction | 0.77 [0.56 1.06] | p=1.00 | 0 | 3053 | 1 | Multicentre international , | | cardiovascular events | no data | | cardiac event (fatal and non fatal ) | no data | | NYHA class improvement | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Multicentre international , 1975 | Practolol 200mg twice daily | placebo | patients recovering from acute myocardial infarction |
|
| Propranolol | acute myocardial infarction, in immediate beta-blockers | vs placebo | NS | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 1.01 [0.78 1.30] | p=1.00 | 0 | 2685 | 21 | Balcon , Barber , Clausen , Curtis , Dotremont , Gupta , Gupta , Hutton , Kahler , Ledwich , Mueller , Multicentre , Nigam , Norris , Norris , Norris , Peter , Pitt , Roberts , Singh , Sloman , | | Coronary death | no data | | Coronary event | no data | | Cardiovascular death | no data | | Fatal MI | no data | | myocardial infarction (fatal and non fatal) | no data | | Death from any cause or hospitalization for any reason | no data | | hospitalisation for heart failure | no data | | Sudden death | no data | | cardiac death | no data | | reinfarction | no data | | cardiovascular events | no data | | cardiac event (fatal and non fatal ) | no data | | NYHA class improvement | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Balcon , 1966 | Propranolol | | | | Barber , 1976 | Propranolol | | | | Clausen , 1966 | Propranolol | | | | Curtis , 1991 | Propranolol 240mg/d | placebo | patients with recent infarction | | Dotremont , 1968 | Propranolol | | | | Gupta , 1982 | Propranolol | | | | Gupta , 1984 | Propranolol (initial dose intravenously) | | | | Hutton , 1979 | Propranolol | | | | Kahler , 1968 | Propranolol | | | | Ledwich , 1968 | Propranolol | | | | Mueller , 1980 | Propranolol (initial dose intravenously) | | | | Multicentre , 1966 | Propranolol | | | | Nigam , 1983 | Propranolol (initial dose intravenously) | | | | Norris , 1968 | Propranolol | | | | Norris , 1978 | Propranolol (initial dose intravenously) | | | | Norris , 1984 | Propranolol (initial dose intravenously) | | | | Peter , 1978 | Propranolol (initial dose intravenously) | | | | Pitt , 1976 | Propranolol | | | | Roberts , 1984 | Propranolol (initial dose intravenously) | | | | Singh , 1985 | Propranolol (initial dose intravenously) | | | | Sloman , 1967 | Propranolol (initial dose intravenously) | | |
|
| Propranolol | acute myocardial infarction, in long term beta-blockers | vs control | NS | - | - | - | - | - | - | - | - | NS | NS | - | NS | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 0.73 [0.37 1.45] | p=1.00 | 0 | 158 | 1 | Aronow , | | Coronary death | no data | | Coronary event | no data | | Cardiovascular death | no data | | Fatal MI | no data | | myocardial infarction (fatal and non fatal) | no data | | Death from any cause or hospitalization for any reason | no data | | hospitalisation for heart failure | no data | | Sudden death | no data | | cardiac death | 0.71 [0.37 1.38] | p=1.00 | 0 | 158 | 1 | Aronow , | | reinfarction | 0.60 [0.14 2.60] | p=1.00 | 0 | 158 | 1 | Aronow , | | cardiovascular events | no data | | cardiac event (fatal and non fatal ) | 0.72 [0.35 1.50] | p=1.00 | 0 | 158 | 1 | Aronow , | | NYHA class improvement | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Aronow , 1997 | Propranolol 30 mg 3 times daily | no propranolol | patients >=62 years of age with New York Heart Association functional class II or III CHF, prior Qwave myocardial infarction, and a LV ejection fraction <40% after 2 months of treatment with diuretics and ACE inhibitors |
|
| Propranolol | acute myocardial infarction, in long term beta-blockers | vs placebo | by 22% | - | - | by 24% | NS | NS | - | - | NS | by 29% | NS | - | NS | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 0.78 [0.65 0.94] | p=0.04 | 0 | 5505 | 4 | Baber , BHAT , Hansteen , Wilcox , | | Coronary death | no data | | Coronary event | no data | | Cardiovascular death | 0.76 [0.61 0.95] | p=0.04 | 0 | 4225 | 2 | BHAT , Wilcox , | | Fatal MI | 1.12 [0.47 2.67] | p=1.00 | 0 | 560 | 1 | Hansteen , | | myocardial infarction (fatal and non fatal) | 1.35 [0.92 1.98] | p=1.00 | 0 | 1280 | 2 | Baber , Hansteen , | | Death from any cause or hospitalization for any reason | no data | | hospitalisation for heart failure | no data | | Sudden death | 0.49 [0.23 1.02] | p=1.00 | 0 | 560 | 1 | Hansteen , | | cardiac death | 0.71 [0.58 0.87] | p=0.04 | 0 | 5117 | 3 | Baber , BHAT , Hansteen , | | reinfarction | 0.86 [0.68 1.09] | p=1.00 | 0 | 5117 | 3 | Baber , BHAT , Hansteen , | | cardiovascular events | no data | | cardiac event (fatal and non fatal ) | 0.73 [0.46 1.18] | p=1.00 | 0 | 560 | 1 | Hansteen , | | NYHA class improvement | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Baber , 1980 | Propranolol 40 mg three times a day | placebo | Men and women with anterior MI | | BHAT , 1982 | Propranolol 180 or 240 mg/day | placebo | mean and women who has experienced at least one MI | | Hansteen , 1982 | Propranolol 40mg four times a day | placebo | high-risk patients who survived acute myocardial infarction | | Wilcox , 1980 | Propranolol 40 mg three times daily(initial dose intravenously) n=132 or atenolol 50 mg twice daily n=127 | placebo | patients with acute MI within the past 24 hours |
|
| Sotalol | acute myocardial infarction, in immediate beta-blockers | vs placebo | NS | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 1.00 [0.02 53.89] | p=1.00 | 0 | 30 | 1 | Lloyd , | | Coronary death | no data | | Coronary event | no data | | Cardiovascular death | no data | | Fatal MI | no data | | myocardial infarction (fatal and non fatal) | no data | | Death from any cause or hospitalization for any reason | no data | | hospitalisation for heart failure | no data | | Sudden death | no data | | cardiac death | no data | | reinfarction | no data | | cardiovascular events | no data | | cardiac event (fatal and non fatal ) | no data | | NYHA class improvement | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Lloyd , 1988 | Sotalol (initial dose intravenously) | | |
|
| Timolol | acute myocardial infarction, in immediate beta-blockers | vs placebo | NS | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 0.74 [0.33 1.66] | p=1.00 | 0 | 576 | 6 | Campbell , Federman , ICSG , Ranganathan , Tonkin , UKCSG , | | Coronary death | no data | | Coronary event | no data | | Cardiovascular death | no data | | Fatal MI | no data | | myocardial infarction (fatal and non fatal) | no data | | Death from any cause or hospitalization for any reason | no data | | hospitalisation for heart failure | no data | | Sudden death | no data | | cardiac death | no data | | reinfarction | no data | | cardiovascular events | no data | | cardiac event (fatal and non fatal ) | no data | | NYHA class improvement | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Campbell , 1984 | Timolol (initial dose intravenously) | | | | Federman , 1984 | Timolol (initial dose intravenously) | | | | ICSG , 1984 | Timolol (initial dose intravenously) | | patients within four hours after onset of symptoms of myocardial infarction | | Ranganathan , 1988 | Timolol (initial dose intravenously) | | | | Tonkin , 1981 | Timolol | | | | UKCSG , 1983 | Timolol | | |
|
| Timolol | acute myocardial infarction, in long term beta-blockers | vs placebo | by 36% | - | - | by 42% | - | - | - | - | by 51% | by 42% | by 38% | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 0.64 [0.49 0.84] | p=0.04 | 0 | 1884 | 1 | Norwegian Multicentre Study Group , | | Coronary death | no data | | Coronary event | no data | | Cardiovascular death | 0.58 [0.44 0.77] | p=0.04 | 0 | 1884 | 1 | Norwegian Multicentre Study Group , | | Fatal MI | no data | | myocardial infarction (fatal and non fatal) | no data | | Death from any cause or hospitalization for any reason | no data | | hospitalisation for heart failure | no data | | Sudden death | 0.49 [0.34 0.71] | p=0.04 | 0 | 1884 | 1 | Norwegian Multicentre Study Group , | | cardiac death | 0.58 [0.44 0.77] | p=0.04 | 0 | 1884 | 1 | Norwegian Multicentre Study Group , | | reinfarction | 0.62 [0.47 0.82] | p=0.04 | 0 | 1884 | 1 | Norwegian Multicentre Study Group , | | cardiovascular events | no data | | cardiac event (fatal and non fatal ) | no data | | NYHA class improvement | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Norwegian Multicentre Study Group , 1981 | Timolol 10mg twice daily | placebo | patients surviving acute myocardial infarction |
|
| Xamoterol | acute myocardial infarction, in immediate beta-blockers | vs placebo | NS | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 1.04 [0.02 54.50] | p=1.00 | 0 | 51 | 1 | McMurray , | | Coronary death | no data | | Coronary event | no data | | Cardiovascular death | no data | | Fatal MI | no data | | myocardial infarction (fatal and non fatal) | no data | | Death from any cause or hospitalization for any reason | no data | | hospitalisation for heart failure | no data | | Sudden death | no data | | cardiac death | no data | | reinfarction | no data | | cardiovascular events | no data | | cardiac event (fatal and non fatal ) | no data | | NYHA class improvement | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| McMurray , 1991 | Xamoterol | | |
|
| Alprenolol | acute myocardial infarction, in long term beta-blockers | vs placebo | NS | - | - | - | - | - | - | - | - | - | NS | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 0.88 [0.60 1.27] | p=1.00 | 0 | 710 | 2 | Andersen , Wilhelmsson , | | Coronary death | no data | | Coronary event | no data | | Cardiovascular death | no data | | Fatal MI | no data | | myocardial infarction (fatal and non fatal) | no data | | Death from any cause or hospitalization for any reason | no data | | hospitalisation for heart failure | no data | | Sudden death | no data | | cardiac death | no data | | reinfarction | 0.90 [0.44 1.88] | p=1.00 | 0 | 230 | 1 | Wilhelmsson , | | cardiovascular events | no data | | cardiac event (fatal and non fatal ) | no data | | NYHA class improvement | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Andersen , 1979 | Alprenolol 5-10 mg intravenously, followed by 200 mg twice a day | placebo | patients years with definite or suspected myocardial infarction | | Wilhelmsson , 1974 | Alprenolol 200mg twice daily | placebo | patient aged 57-67 years discharge alive after acute myocardial infarction |
|
| Carvedilol | acute myocardial infarction, in long term beta-blockers | vs placebo | - | - | - | NS | NS | NS | - | - | - | NS | NS | - | NS | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | no data | | Coronary death | no data | | Coronary event | no data | | Cardiovascular death | 0.63 [0.10 3.89] | p=1.00 | 0 | 146 | 1 | Basu , | | Fatal MI | 0.63 [0.10 3.89] | p=1.00 | 0 | 146 | 1 | Basu , | | myocardial infarction (fatal and non fatal) | 0.52 [0.18 1.48] | p=1.00 | 0 | 146 | 1 | Basu , | | Death from any cause or hospitalization for any reason | no data | | hospitalisation for heart failure | no data | | Sudden death | no data | | cardiac death | 0.64 [0.10 3.95] | p=1.00 | 0 | 151 | 1 | Basu , | | reinfarction | 0.47 [0.14 1.65] | p=1.00 | 0 | 146 | 1 | Basu , | | cardiovascular events | no data | | cardiac event (fatal and non fatal ) | 0.55 [0.27 1.12] | p=1.00 | 0 | 146 | 1 | Basu , | | NYHA class improvement | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Basu , 1997 | Carvedilol target dose 25 mg BID | placebo | Patients with acute MI <24h |
|
| Carvedilol | heart failure, in all type of heart failure | vs placebo | by 31% | - | - | by 24% | - | - | by 17% | by 28% | NS | - | - | - | - | NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 0.69 [0.58 0.81] | p=0.04 | 0 | 5905 | 10 | ANZ-HeFT, COPERNICUS, CAPRICORN, Metra, Olsen, Krum, Bristow (MOCHA), Parker, Colucci, Cohn, | | Coronary death | no data | | Coronary event | no data | | Cardiovascular death | 0.76 [0.61 0.96] | p=0.04 | 0 | 2652 | 3 | ANZ-HeFT, CAPRICORN, Parker, | | Fatal MI | no data | | myocardial infarction (fatal and non fatal) | no data | | Death from any cause or hospitalization for any reason | 0.83 [0.74 0.93] | p=0.04 | 0 | 5865 | 9 | ANZ-HeFT, COPERNICUS, CAPRICORN, Olsen, Krum, Bristow (MOCHA), Parker, Colucci, Cohn, | | hospitalisation for heart failure | 0.72 [0.62 0.82] | p=0.04 | 0 | 5905 | 10 | ANZ-HeFT, COPERNICUS, CAPRICORN, Metra, Olsen, Krum, Bristow (MOCHA), Parker, Colucci, Cohn, | | Sudden death | 0.87 [0.39 1.94] | p=1.00 | 0 | 278 | 1 | Parker, | | cardiac death | no data | | reinfarction | no data | | cardiovascular events | no data | | cardiac event (fatal and non fatal ) | no data | | NYHA class improvement | 1.13 [0.86 1.47] | p=1.00 | 0 | 1512 | 6 | ANZ-HeFT, Olsen, Krum, Bristow (MOCHA), Parker, Colucci, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| ANZ-HeFT, 1997 | carvedilol target dose 25mg twice daily | placebo | chronic stable heart failure, NYHA 1-3 | | COPERNICUS, 2002 | carvedilol traget dose of 25 mg twice daily | placebo | patients with symptoms of heart failure at rest or on minimal exertion and with an ejection fraction <25% (but not volume-overloaded) | | CAPRICORN, 2001 | carvedilol target dose 25mg twice daily | placebo | proven acute myocardial infarction and a left-ventricular ejection fraction of <=40% | | Metra, 1994 | carvedilol | placebo | NYHA 2-3, IDC | | Olsen, 1995 | carvedilol | placebo | NYHA 2-4, IDC/CAD | | Krum, 1995 | carvedilol 25 mg twice daily during 14 weeks | placebo | Patients with advanced heart failure(NYHA 3-4), EF <=0.35 | | Bristow (MOCHA), 1996 | carvedilol | placebo | NYHA 2-4, IDC/CAD | | Parker, 1996 | carvediloltarget dose 25 mg twice daily | placebo | patients with heart failure and ejection fraction<0.35 | | Colucci, 1996 | carvedilol | placebo | mild symptomatic heart failure; ejection fraction<=0.35; 6-minute walk test of 450-550m; on optimal standard therapy including ACE inhibitors | | Cohn, 1997 | carvedilol | placebo | NYHA 3-4, IDC/CAD |
|
| Carvedilol | heart failure, in all type of heart failure | vs enalapril | NS | - | - | NS | - | - | - | NS | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 0.99 [0.46 2.15] | p=1.00 | 0 | 381 | 1 | CARMEN (carvedilol alone), | | Coronary death | no data | | Coronary event | no data | | Cardiovascular death | 0.92 [0.42 2.02] | p=1.00 | 0 | 381 | 1 | CARMEN (carvedilol alone), | | Fatal MI | no data | | myocardial infarction (fatal and non fatal) | no data | | Death from any cause or hospitalization for any reason | no data | | hospitalisation for heart failure | 0.75 [0.34 1.62] | p=1.00 | 0 | 381 | 1 | CARMEN (carvedilol alone), | | Sudden death | no data | | cardiac death | no data | | reinfarction | no data | | cardiovascular events | no data | | cardiac event (fatal and non fatal ) | no data | | NYHA class improvement | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| CARMEN (carvedilol alone), 2004 | carvedilol (target 25 mg bid) | enalapril (target 10 mg bid) | patients with mild heart failure |
|
| Carvedilol | heart failure, in all type of heart failure | vs metoprolol | by 14% | - | - | by 18% | - | - | NS | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 0.86 [0.74 0.99] | p=0.04 | 0 | 3029 | 1 | COMET, | | Coronary death | no data | | Coronary event | no data | | Cardiovascular death | 0.82 [0.71 0.96] | p=0.04 | 0 | 3029 | 1 | COMET, | | Fatal MI | no data | | myocardial infarction (fatal and non fatal) | no data | | Death from any cause or hospitalization for any reason | 0.97 [0.82 1.14] | p=1.00 | 0 | 3029 | 1 | COMET, | | hospitalisation for heart failure | no data | | Sudden death | no data | | cardiac death | no data | | reinfarction | no data | | cardiovascular events | no data | | cardiac event (fatal and non fatal ) | no data | | NYHA class improvement | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| COMET, 2003 | carvedilol (target dose 25 mg twice daily) | metoprolol tartrate target dose 50 mg twice daily | chronic heart failure (NYHA II–IV) with a previous admission for a cardiovascular reason and ejection fraction of less than 0·35, and have been treated optimally with diuretics and angiotensinconverting enzyme inhibitors unless not tolerated. |
|
| Carvedilol | heart failure, in elderly patients | vs placebo | by 31% | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 0.69 [0.54 0.89] | p=0.04 | 0 | -36 | 2 | Carvedilol U.S. Trials (elderly subgroup), COPERNICUS (elderly subgroup), | | Coronary death | no data | | Coronary event | no data | | Cardiovascular death | no data | | Fatal MI | no data | | myocardial infarction (fatal and non fatal) | no data | | Death from any cause or hospitalization for any reason | no data | | hospitalisation for heart failure | no data | | Sudden death | no data | | cardiac death | no data | | reinfarction | no data | | cardiovascular events | no data | | cardiac event (fatal and non fatal ) | no data | | NYHA class improvement | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Carvedilol U.S. Trials (elderly subgroup), 1996 | Carvedilol | placebo | Patients aged 65 years and older | | COPERNICUS (elderly subgroup), 2001 | Carvedilol | placebo | Patients aged 59 years and older |
|
